1.52%| Prev Close: | 4.19 |
|---|---|
| Open: | 4.17 |
| Bid: | 4.23 x 1300 |
| Ask: | 4.24 x 1100 |
| 1y Target Est: | 5.64 |
| Beta: | 0.35 |
| Next Earnings Date: | N/A |
| Day's Range: | 4.12 - 4.27 |
|---|---|
| 52wk Range: | 3.21 - 11.30 |
| Volume: | 222,611 |
| Avg Vol (3m): | 889,729 |
| Market Cap: | 569.33M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.60 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Idenix Pharmaceuticals Reports First Quarter 2013 Financial Resultsat noodls(Wed 1 May)
- Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)at noodls(Tue 9 Apr)
- Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Phase of the Interferenceat noodls(Sat 23 Mar)
- Idenix Pharmaceuticals Provides Update on IDX184 and IDX19368 Development Programsat noodls(Tue 5 Feb)
- Idenix Pharmaceuticals Announces Collaboration With Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV)at noodls(Mon 28 Jan)
- Idenix Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conferenceat noodls(Thu 3 Jan)
- Idenix Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conferenceat noodls(Thu 6 Dec)
- Idenix Pharmaceuticals to Present at the 2012 Deutsche Bank Access BioFEST Conferenceat noodls(Tue 27 Nov)
- Idenix Pharmaceuticals Reports Clinical Data for HCV Drug Candidates - IDX719 and IDX184 - at the American Association for the Study of Liver Diseases (AASLD) Annual Meetingat noodls(Sun 11 Nov)
- PropThink: BioCryst and Presidio's Priorities May Shift with FDA ConcernsACN Newswire(Thu 1 Nov)
Press Releases
- PropThink: BioCryst and Presidio's Priorities May Shift with FDA ConcernsACN Newswire(Thu 1 Nov)
- PropThink: Vertex Drops One Drug, Advances Another as HCV Segment Heats UpACN Newswire(Thu 27 Sep)
- PropThink: ACHN, IDIX Pair Trade Continues To Gain TractionACN Newswire(Wed 19 Sep)